Pharmaceutical

Verekitug by Upstream Bio for Rhinosinusitis: Likelihood of Approval

Verekitug is under clinical development by Upstream Bio and currently in Phase II for Rhinosinusitis.

Feb 8, 2024 - 18:00
Verekitug is under clinical development by Upstream Bio and currently in Phase II for Rhinosinusitis.
Read the original article

Tags:

Previous Article

Tapotoclax by Amgen for Myelodysplastic Syndrome: Likelihood of Approval

Next Article

J&J’s Autoimmune Drug Prospect Meets Phase 3 Goal, Inches Closer to Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CDC says it’s too soon to assess risk posed by new Covid subvariant

CDC says it’s too soon to assess risk posed by new Covi...

Aug 23, 2023

Purdue receives clearance for opioid overdose injector for younger individuals

Purdue receives clearance for opioid overdose injector ...

Aug 9, 2024

Lilly to acquire biopharma firm Versanis for $1.9bn

Lilly to acquire biopharma firm Versanis for $1.9bn

Jul 17, 2023